Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028

Report Code : TIPRE00009519 | Region : Global | Industry : Pharmaceuticals | Published Date : 30/May/2022
Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (PET and SPECT), PET Product (F-18, C-11, and Ga68-PSMA), and End User (Hospitals, Clinics, and Others)

The global prostate cancer nuclear medicine diagnostics market is expected to grow from US$ 720.12 million in 2022 to US$ 1,315.66 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028.

Prostate cancer affects the prostate glands in males. Prostate cancer is common cancer following skin cancer in males. Common determinants responsible for prostate cancer are family history, old age, and race. Nuclear medicine is imaging that needs radioactive materials. It is a helpful method to identify and treat prostate cancer and helps radiologists conclude the stage of cancer.

In terms of occurrence, prostate cancer (PCa) is the fourth most common cancer across the US. The rising incidences of prostate cancer in the country led to the increased use of nuclear medicines for its treatment. This cancer is more likely to grow in older adults. Thus, the rising cases of prostate cancer offer substantial growth opportunities for the prostate cancer nuclear medicine diagnostics market during the forecast period.

Based on type, the prostate cancer nuclear medicine diagnostics market is bifurcated into SPECT and PET. The PET segment held the largest share of the market in 2021 and is anticipated to register the highest CAGR during the forecast period. A positron Emission Tomography (PET) scan is usually the most effective way to restage recurrent prostate cancer. After prostate cancer treatment, PET scanning may be used to determine the effectiveness of the treatment and is now commonly being used to detect biochemically recurrent prostate cancer for restaging.

Rising research activities for developing novel imaging agents to improve prostate cancer detection and the development of novel imaging agents to improve prostate cancer detection are key factors driving the growth of nuclear medicine diagnostics. Researchers are conducting several studies to introduce new diagnostic agents for PET with higher efficiency than the existing agents. For instance, in March 2018, a study in The Journal of Nuclear Medicine demonstrated a novel PET agent named Copper-64 Chloride (64CuCl2) to detect prostate cancer. This new imaging agent exhibited a higher detection rate when compared with Fluorine-18-Choline (18F-choline). The adoption of PET as a diagnostic tool is significantly increasing, as it offers higher accuracy to that other diagnostic techniques. Accuracy in diagnosis has a direct impact on decision-making and treatment monitoring processes. Increasing demand for these diagnostic procedures is expected to fuel the growth of the prostate cancer nuclear medicine diagnostics market during the forecast period. Reimbursement policies is expected to further fuel the development of nuclear medicine diagnostics. Several programs such as Medicaid, Medicare, and the Health Insurance programs in the US are expected to create growth opportunities for the market players. For instance, the Centers for Medicare & Medicaid Services (CMS) covers PET services through National Coverage Determination (NCD) which includes tracers necessary for the diagnosis of prostate cancer. Therefore, due to the factors mentioned above, PET is expected to hold the largest market share.

A few of the key primary and secondary sources referred to while preparing the report on the prostate cancer nuclear medicine diagnostics market are the World Health Organization (WHO), the Centers for Disease Control and Prevention (CDC), and Scientific Institute for Research, Hospitalization, and Healthcare (IRCCS).

List of Companies

1. Blue Earth Diagnostics Limited

2. ImaginAB

3. Curium

4. Jubilant Radiopharma

5. NCM-USA LLC

6. ABX Advanced Biochemical Compounds GmbH

7. Telix Pharmaceuticals Ltd.

8. Novartis AG

9. Theragonostics

10. Lantheus Medical Imaging Inc.

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market – By Type

1.3.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market – By PET Product

1.3.3 Global Prostate Cancer Nuclear Medicine Diagnostics Market – By End User

1.3.4 Global Prostate Cancer Nuclear Medicine Diagnostics Market – By Geography

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Prostate Cancer Nuclear Medicine Diagnostics Market – Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.2.2 Europe PEST Analysis

4.2.3 Asia Pacific PEST Analysis

4.2.4 Middle East And Africa PEST Analysis

4.2.5 South And Central America PEST Analysis

4.3 Experts Opinion

5. Prostate Cancer Nuclear Medicine Diagnostics Market– Key Market Dynamics

5.1 Market Drivers

5.1.1 Rising Prevalence of Prostate Cancer

5.1.2 Surging Demand for Early and Precise Diagnosis of Prostate Cancer

5.2 Market Restraints

5.2.1 High Cost Related to the Prostate Cancer Diagnostics and Treatment

5.3 Market Opportunities

5.3.1 Growing Use of Radiopharmaceuticals in Prostate Cancer

5.4 Future Trends

5.4.1 Increasing Research Activities for Development of Innovative Imaging Agents

5.5 Impact Analysis

6. Prostate Cancer Nuclear Medicine Diagnostics Market– Global Analysis

6.1 Global Prostate Cancer Nuclear Medicine Diagnostics Market Revenue Forecast and Analysis

6.2 Global Prostate Cancer Nuclear Medicine Diagnostics Market, By Geography - Forecast and Analysis

6.3 Company Analysis

6.3.1 Market Positioning of Key Players

6.3.2 Comparative Company Analysis

6.3.3 Growth Strategy Analysis

6.3.4 Performance of Key Players

6.3.4.1 Novartis AG

6.3.4.2 Jubilant Radiopharma

6.3.4.3 Curium

7. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By Type

7.1 Overview

7.2 Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2022 & 2028 (%)

7.3 SPECT

7.3.1 Overview

7.3.2 SPECT: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)

7.4 PET

7.4.1 Overview

7.4.2 PET: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts to 2028 (US$ Million)

8. Prostate Cancer Nuclear Medicine Diagnostics Market Analysis – By PET Product

8.1 Overview

8.2 Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2022 & 2028 (%)

8.3 F-18

8.3.1 Overview

8.3.2 F-18: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

8.4 C-11

8.4.1 Overview

8.4.2 C-11: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

8.5 GA 68 PSMA

8.5.1 Overview

8.5.2 GA 68 PSMA: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9. Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028 – End User

9.1 Overview

9.2 Prostate Cancer Nuclear Medicine Diagnostics Market Share by End User- 2022 & 2028 (%)

9.3 Hospitals

9.3.1 Overview

9.3.2 Hospitals: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9.4 Clinics

9.4.1 Overview

9.4.2 Clinics: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

9.5 Others

9.5.1 Overview

9.5.2 Others: Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

10. Global Prostate Cancer Nuclear Medicine Diagnostics Market – Geographic Analysis

10.1 North America: Prostate Cancer Nuclear Medicine Diagnostics Market

10.1.1 Overview

10.1.2 North America: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.3 North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.1.4 North America: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.1.5 North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ Million)

10.1.6 North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2021 & 2028 (%)

10.1.6.1 US: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.6.1.1 Overview

10.1.6.1.2 US: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.6.1.3 US: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.1.6.1.4 US: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.1.6.1.5 US: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.1.6.2 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.6.2.1 Overview

10.1.6.2.2 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.6.2.3 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.1.6.2.4 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.1.6.2.5 Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.1.6.3 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.6.3.1 Overview

10.1.6.3.2 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.1.6.3.3 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.1.6.3.4 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.1.6.3.5 Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.2 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market

10.2.1 Overview

10.2.2 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.3 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

10.2.4 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

10.2.5 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

10.2.6 Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)

10.2.6.1 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.1 Overview

10.2.6.1.2 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.3 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.4 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

10.2.6.1.5 Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2 France: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.1 Overview

10.2.6.2.2 France: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.3 France: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.4 France: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

10.2.6.2.5 France: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3 UK: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.1 Overview

10.2.6.3.2 UK: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.3 UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.4 UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

10.2.6.3.5 UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.1 Overview

10.2.6.4.2 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.3 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.4 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

10.2.6.4.5 Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.1 Overview

10.2.6.5.2 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.3 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.4 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

10.2.6.5.5 Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.1 Overview

10.2.6.6.2 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.3 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.4 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

10.2.6.6.5 Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

10.3 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market

10.3.1 Overview

10.3.2 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market - Revenue and Forecast to 2028 (US$ Million)

10.3.3 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.3.4 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.3.5 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.3.6 Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)

10.3.6.1 China: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.1.1 Overview

10.3.6.1.2 China: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.1.3 China: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.3.6.1.4 China: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.3.6.1.5 China: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.3.6.2 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.2.1 Overview

10.3.6.2.2 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.2.3 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.3.6.2.4 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.3.6.2.5 Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.3.6.3 India: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.3.1 Overview

10.3.6.3.2 India: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.3.3 India: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.3.6.3.4 India: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.3.6.3.5 India: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.3.6.4 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.4.1 Overview

10.3.6.4.2 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.4.3 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.3.6.4.4 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.3.6.4.5 Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.3.6.5 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.5.1 Overview

10.3.6.5.2 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.5.3 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.3.6.5.4 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.3.6.5.5 South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.3.6.6 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.6.1 Overview

10.3.6.6.2 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ Million)

10.3.6.6.3 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type, 2019–2028 (US$ Million)

10.3.6.6.4 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product, 2019–2028 (US$ Million)

10.3.6.6.5 Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ million)

10.4 Middle East & Africa Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028

10.4.1 Overview

10.4.2 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.4.3 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.4.4 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.4.5 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ Million)

10.4.6 Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2021 & 2028 (%)

10.4.6.1 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.4.6.1.1 Overview

10.4.6.1.2 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.4.6.1.3 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.4.6.1.4 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.4.6.1.5 UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.4.6.2 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.4.6.2.1 Overview

10.4.6.2.2 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.4.6.2.3 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.4.6.2.4 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.4.6.2.5 Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.4.6.3 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.4.6.3.1 Overview

10.4.6.3.2 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.4.6.3.3 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.4.6.3.4 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.4.6.3.5 South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.4.6.4 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.4.6.4.1 Overview

10.4.6.4.2 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (US$ ‘Million)

10.4.6.4.3 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (US$ ‘Million)

10.4.6.4.4 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product, 2019–2028 (US$ ‘Million)

10.4.6.4.5 Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (US$ ‘Million)

10.5 South and Central America Prostate Cancer Nuclear Medicine Diagnostics Market Revenue and Forecasts To 2028

10.5.1 Overview

10.5.2 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)

10.5.3 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (USD Million)

10.5.4 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2019–2028 (USD Million)

10.5.5 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (USD Million)

10.5.6 South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Country, 2022 & 2028 (%)

10.5.6.1 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.1.1 Overview

10.5.6.1.2 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.1.3 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (USD Million)

10.5.6.1.4 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2019–2028 (USD Million)

10.5.6.1.5 Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (USD Million)

10.5.6.2 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.2.1 Overview

10.5.6.2.2 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.2.3 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (USD Million)

10.5.6.2.4 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product, 2019–2028 (USD Million)

10.5.6.2.5 Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User, 2019–2028 (USD Million)

10.5.6.3 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.3.1 Overview

10.5.6.3.2 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market – Revenue and Forecast to 2028 (USD Million)

10.5.6.3.3 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type, 2019–2028 (USD Million)

10.5.6.3.4 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market , by PET Product, 2019–2028 (USD Million)

10.5.6.3.5 Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market , by End User, 2019–2028 (USD Million)

11. Impact of COVID-19 Pandemic on Global Prostate Cancer Nuclear Medicine Diagnostics Market

11.1 North America: Impact Assessment of COVID-19 Pandemic

11.2 Europe: Impact Assessment of COVID-19 Pandemic

11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic

11.4 Middle East and Africa: Impact Assessment of COVID-19 Pandemic

11.5 South and Central America: Impact Assessment of COVID-19 Pandemic

12. Prostate Cancer Nuclear Medicine Diagnostics Market–Industry Landscape

12.1 Overview

12.2 Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market, 2021-2028

12.3 Inorganic Growth Strategies

12.3.1 Overview

12.4 Organic Growth Strategies

12.4.1 Overview

13. Company Profiles

13.1 Blue Earth Diagnostics Limited

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 ImaginAb

13.2.1 1.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Curium

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Jubilant Radiopharma

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 NCM-USA LLC

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 ABX advanced biochemical compounds GmbH

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Telix Pharmaceuticals Ltd.

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Novartis AG

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Theragnostics

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 Lantheus Medical Imaging, Inc.

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1. North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 2. North America: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 3. North America: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 4. US: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 5. US: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 6. US: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 7. Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 8. Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 9. Canada: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 10. Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 11. Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 12. Mexico: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 13. Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 14. Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 15. Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 16. Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 17. Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 18. Germany: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 19. France: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 20. France: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 21. France: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 22. UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 23. UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 24. UK: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 25. Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 26. Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 27. Italy: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 28. Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 29. Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 30. Spain: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 31. Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 32. Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 33. Rest of Europe: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 34. Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 35. Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product – Revenue and Forecast to 2028 (US$ Million)

Table 36. Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 37. China: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 38. China: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 39. China Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 40. Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 41. Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 42. Japan: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 43. India: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type– Revenue and Forecast to 2028 (US$ Million)

Table 44. India: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product– Revenue and Forecast to 2028 (US$ Million)

Table 45. India Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 46. Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 47. Australia: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product – Revenue and Forecast to 2028 (US$ Million)

Table 48. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 49. South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 50. South Korea: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product – Revenue and Forecast to 2028 (US$ Million)

Table 51. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 52. Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By Type – Revenue and Forecast to 2028 (US$ Million)

Table 53. Rest of Asia Pacific: Prostate Cancer Nuclear Medicine Diagnostics Market, By PET Product – Revenue and Forecast to 2028 (US$ Million)

Table 54. Rest of Asia Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ million)

Table 55. Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 56. Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 57. Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 58. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 59. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 60. UAE: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 61. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 62. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 63. Saudi Arabia: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 64. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 65. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 66. South Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 67. Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (US$ ‘Million)

Table 68. Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, PET Product – Revenue and Forecast to 2028 (US$ ‘Million)

Table 69. Rest of Middle East and Africa: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User – Revenue and Forecast to 2028 (US$ ‘Million)

Table 70. South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 71. South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2028 (USD Million)

Table 72. South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 73. Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 74. Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2028 (USD Million)

Table 75. Brazil: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 76. Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 77. Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2028 (USD Million)

Table 78. Argentina: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 79. Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by Type – Revenue and Forecast to 2028 (USD Million)

Table 80. Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by PET Product – Revenue and Forecast to 2028 (USD Million)

Table 81. Rest of South and Central America: Prostate Cancer Nuclear Medicine Diagnostics Market, by End User– Revenue and Forecast to 2028 (USD Million)

Table 82. Recent Inorganic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market

Table 83. Recent Organic Growth Strategies in the Prostate Cancer Nuclear Medicine Diagnostics Market

Table 84. Glossary of Terms, Prostate Cancer Nuclear Medicine Diagnostics Market

List of Companies

1. Blue Earth Diagnostics Limited

2. ImaginAB

3. Curium

4. Jubilant Radiopharma

5. NCM-USA LLC

6. ABX Advanced Biochemical Compounds GmbH

7. Telix Pharmaceuticals Ltd.

8. Novartis AG

9. Theragonostics

10. Lantheus Medical Imaging Inc.

Reason To Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the prostate cancer nuclear medicine diagnostics market.

• Highlights key business priorities in order to assist companies to realign their business strategies.

• The key findings and recommendations highlight crucial progressive industry trends in the global prostate cancer nuclear medicine diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.

• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Prostate Cancer Nuclear Medicine Diagnostics Market Forecast to 2028 )
  • Single User Price $4,550$3,640
  • Site Price $6,550$5,240
  • Enterprise Price $8,550$6,840
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry